

Collaborative Working Project executive summary

Project title	A Collaborative Working Project to pilot a structured lipid service between East Lancashire NHS Trust, Oakenhurst Medical practice in Blackburn, North West Coast Academic Health Science Network (NWCAHSN) and Sanofi to pilot a structured lipid service.
Partner organisation/s	North West Coast Academic Health Science Network. Sanofi.
Project rationale	<ul style="list-style-type: none"> • Optimisation of oral lipid lowering therapies for patients with FH and patients requiring secondary prevention following cardiovascular event • Identification of patients who may benefit from lipid optimisation services • Specialist nurse-led follow up of patients, including monitoring of treatment, side effects and appropriate referrals to relevant services • Develop links between primary and secondary care clinicians (nursing, GP, pharmacist) to develop a lipid treatment pathway across the health economy • Implement lipid treatment pathway, including education events and training of relevant primary and secondary care professionals • Use of prescribing pharmacists to achieve the standards set out in NICE TA393 and TA394 to work alongside existing medical teams to optimise therapies, including referral to consultant endocrinologist or consultant cardiologist if appropriate. • Support access to relevant diagnostic and screening services for FH.
Project period	<i>Q1 2022 to Q3 2022</i>

<p>Project objectives</p>	<p>Predicted Benefits: -</p> <p>Patients</p> <ul style="list-style-type: none"> • Increased diagnosis rate and improved management of high-risk cardiovascular patients with elevated LDL-C. • Optimisation of treatment and lipid management with access to new Endocrinology led MDT lipid service and access to genetic cascade screening. • Care closer to home • Patient empowerment and engagement in terms of their diagnosis and subsequent clinical management plan. Support implementation of NICE CG181 <p>The NHS:</p> <ul style="list-style-type: none"> • Development of an Endocrinologist Led MDT specialist lipid service. • Increased capacity of lipid service • Reduction in waiting time. • Alignment with NHS Long term plan and CVD Prevent Audit in Primary Care. • Support implementation of NICE CG181 • Pilot of a practice-based Nurse led service that could be implemented and commissioned across other Primary Care Networks/elsewhere. <p>Sanofi:</p> <ul style="list-style-type: none"> • The project aims to increase the diagnosis rate and improved management of high-risk cardiovascular patients with elevated LDL-C - Patients diagnosed with these conditions will be treated with cholesterol lowering medicines which may include Sanofi medicines for suitable patients in line with NICE TA393 / TA394 and or local / national guidelines. • Demonstrates collaborative working and enhanced reputation with the NHS to the benefit of patients that identifies scalable solutions.
<p>Contact details</p>	<p>Dr Julia Reynolds – Associate Director of Transformation, Innovation Agency North West Coast Academic Health Science Network, Vanguard House Keckwick Lane, Warrington, WA4 4AB</p> <p>Julia.Reynolds@innovationagencynwc.nhs.uk</p>

	<p>Paul Naish - Head of Market Access</p> <p>GB-MarketAccess@sanofi.com</p>
--	---